We are live on
!
Find out more
HS
HighVista Strategies Portfolio holdings
AUM
$362M
1-Year Est. Return
230.96%
This Fund
S&P 500
This Quarter
Est. Return
+15.86%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$219M
AUM Growth
+$95.8M
(+78%)
Cap. Flow
+$80.7M
Cap. Flow
% of AUM
36.91%
Top 10 Holdings %
Top 10 Hldgs %
33.7%
Holding
163
New
55
Increased
48
Reduced
23
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco DB Commodity Index Tracking Fund
DBC
|
+$32.3M |
| 2 |
AJRD
Aerojet Rocketdyne Holdings
AJRD
|
+$3.42M |
| 3 |
TXNM
TXNM Energy Inc
TXNM
|
+$3.29M |
| 4 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$3.26M |
| 5 |
Indivior Pharmaceuticals
INDV
|
+$2.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 1000 Value ETF
IWD
|
+$4.25M |
| 2 |
Coupang
CPNG
|
+$4.1M |
| 3 |
OSH
Oak Street Health, Inc.
OSH
|
+$3.46M |
| 4 |
TGNA
TEGNA Inc
TGNA
|
+$2.44M |
| 5 |
First Horizon
FHN
|
+$2.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.57% |
| 2 | Technology | 13.44% |
| 3 | Communication Services | 5.29% |
| 4 | Consumer Discretionary | 4.52% |
| 5 | Financials | 3.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
KE Holdings
BEKE
$18.7B
| $392K | 0.18% |
26,407
+15,127
| +134% | +$247K |
|
127
Travere Therapeutics
TVTX
$5.73B
| $390K | 0.18% |
25,397
-96,437
| -79% | -$1.75M |
|
128
United Therapeutics
UTHR
$22.6B
| $385K | 0.18% |
1,742
-1,462
| -46% | -$324K |
|
129
Ascendis Pharma A/S
ASND
$16.8B
| $373K | 0.17% |
4,175
-3,163
| -43% | -$275K |
|
130
Natera
NTRA
$45.6B
| $353K | 0.16% |
+7,255
| New | +$370K |
|
131
Ultragenyx Pharmaceutical
RARE
$2.63B
| $338K | 0.15% |
+7,326
| New | +$340K |
|
|
SWTX
132
DELISTED
SpringWorks Therapeutics
SWTX
| $306K | 0.14% |
11,688
-5,959
| -34% | -$157K |
|
133
Krystal Biotech
KRYS
$9.85B
| $297K | 0.14% |
2,530
-8,528
| -77% | -$871K |
|
134
Amylyx Pharmaceuticals
AMLX
$2.56B
| $297K | 0.14% |
+13,748
| New | +$371K |
|
135
Agilent Technologies
A
$42.2B
| – | – |
-1,890
| Closed | -$261K |
|
|
AKRO
136
DELISTED
Akero Therapeutics
AKRO
| – | – |
-18,629
| Closed | -$713K |
|
|
AMRN
137
Amarin Corp
AMRN
$301M
| – | – |
-25,034
| Closed | -$751K |
|
138
Arvinas
ARVN
$588M
| – | – |
-19,197
| Closed | -$524K |
|
139
Biogen
BIIB
$30.2B
| – | – |
-2,743
| Closed | -$763K |
|
|
140
Coupang
CPNG
$29.4B
| – | – |
-256,264
| Closed | -$4.1M |
|
141
Dyne Therapeutics
DYN
$4.98B
| – | – |
-102,431
| Closed | -$1.18M |
|
142
Ferguson
FERG
$50.1B
| – | – |
-1,840
| Closed | -$246K |
|
|
143
First Horizon
FHN
$12B
| – | – |
-135,400
| Closed | -$2.41M |
|
|
144
iShares Russell 1000 Value ETF
IWD
$84.2B
| – | – |
-27,900
| Closed | -$4.25M |
|
145
Kymera Therapeutics
KYMR
$8.93B
| – | – |
-25,530
| Closed | -$756K |
|
146
LPL Financial
LPLA
$29.4B
| – | – |
-1,700
| Closed | -$344K |
|
|
NOAH
147
Noah Holdings
NOAH
$594M
| – | – |
-14,760
| Closed | -$244K |
|
148
PTC Therapeutics
PTCT
$6.16B
| – | – |
-16,535
| Closed | -$801K |
|
149
Replimune Group
REPL
$1.14B
| – | – |
-17,231
| Closed | -$304K |
|
|
RNAM
150
DELISTED
Avidity Biosciences
RNAM
| – | – |
-16,733
| Closed | -$257K |
|
Similar funds
SIAG
WI
MS
WTFG
VIA
A6
PI
ACM
HighVista Strategies's Q2 2023 Portfolio in Review
As of Q2 2023, HighVista Strategies held 163 positions worth $219M, up 78% from $123M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
HighVista Strategies deployed $80.7M of net new capital in Q2 2023, opening 55 new positions and adding to 48 existing holdings. Its largest new stake was Aerojet Rocketdyne Holdings: 61,520 shares worth $3.38M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 67% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Travere Therapeutics, an estimated $1.75M trimmed.
- HighVista Strategies's largest Q2 2023 buy was Aerojet Rocketdyne Holdings: 61,520 shares worth $3.38M.
- HighVista Strategies added most to Invesco DB Commodity Index Tracking Fund in Q2 2023, an estimated $32.3M increase.
- HighVista Strategies's biggest Q2 2023 reduction was Travere Therapeutics, cutting an estimated $1.75M.
- HighVista Strategies fully exited iShares Russell 1000 Value ETF in Q2 2023, selling an estimated $4.25M.
- HighVista Strategies's ten largest holdings make up 34% of its $219M portfolio in Q2 2023.
- HighVista Strategies opened 55 new positions and closed 29 in Q2 2023.
- HighVista Strategies's portfolio value rose 78% quarter-over-quarter to $219M.
Based on HighVista Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.